These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2319257)

  • 1. Human spleen and peripheral blood lymphocytes activated by interleukin-2 have similar phenotypic and functional characteristics.
    Voltarelli JC; Rayner AA; Garovoy MR; Stites DP
    J Biol Response Mod; 1990 Feb; 9(1):103-7. PubMed ID: 2319257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant interleukin-2-activated intracavitary lymphocytes: phenotypic characteristics and effector function.
    Umiel T; Monselise J; Klein T; Rakovsky E; Fenig E; Lurie H; Adler A
    J Biol Response Mod; 1989 Aug; 8(4):409-21. PubMed ID: 2787838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of natural killer effectors from human thymus with recombinant IL-2.
    Michon JM; Caligiuri MA; Hazanow SM; Levine H; Schlossman SF; Ritz J
    J Immunol; 1988 May; 140(10):3660-7. PubMed ID: 3258886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
    Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
    J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
    Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
    Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
    Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
    J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
    Atzpodien J; Gulati SC
    Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.
    Perussia B; Ramoni C; Anegon I; Cuturi MC; Faust J; Trinchieri G
    Nat Immun Cell Growth Regul; 1987; 6(4):171-88. PubMed ID: 2960890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3.
    Okuno K; Ohnishi H; Shilayama Y; Hirohata T; Ozaki M; Yasutomi M
    Mol Biother; 1992 Jun; 4(2):83-6. PubMed ID: 1515099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
    McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
    J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
    Whiteside TL; Wang YL; Selker RG; Herberman RB
    Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.